Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 6.2.5.4 Economic evidence Published literature One health economic study was identified with the relevant comparison and has been included in . This is summarised in the health economic evidence profile below (Table 55) and the health economic evidence table in Appendix G. Four economic studies relating to this review question were identified but were selectively excluded due to the availability of more applicable evidence73 . These are listed in Appendix I, with reasons for exclusion given. See also the health economic study selection flow chart in Appendix D. Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Table 55: Health economic evidence profile: IV iron versus placebo Study Applicability Limitations Other comments Incremental cost Incremental effects Cost- effectiveness Uncertainty Gutzwiller Directly applicable (a) Potentially serious limitations (b) Within-trial analysis of FAIR- . Comparators: 1. No iron treatment 2. Iron repletion with ferric carboxymaltose IV bolus injection 24 week follow-up QALY gained Probability Intervention 2 cost- effective ( 20K/30K threshold): Univariate and probabilistic sensitivity analysis undertaken. Frequency and duration of hospitalisation, QALY difference, and cost of hospital day were the most influential parameters. None of the parameters tested resulted in an ICER above 20,000 per QALY gained. Abbreviations: ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life years; RCT: randomised controlled trial (a) The FAIR-HF trial did not include British participants, but was mostly performed in European countries with a predominantly Caucasian population. This is unlikely to change the conclusions of cost-effectiveness. (b) Short time horizon may not capture full costs and effects of the intervention. Lack of detailed medical resource use data. 